Cutaneous hyperpigmentation induced by apremilast

Cutaneous hyperpigmentation induced by apremilast Case reportApremilast is an oral inhibitor of phosphodiesterase‐4 (PDE4) recently approved for the treatment of psoriasis and psoriatic arthritis (PsA).We report the case of a 70‐year‐old female patient affected with severe psoriasis and PsA for more than 30 years, who developed cutaneous skin hyperpigmentation while treated with oral apremilast 30 mg/bid (Fig. ).Patient before (a) and during apremilast treatment (b) exhibiting increase in size and darkening of the solar lentigines resembling intense UV exposureOver decades, she had been variously treated with PUVA, acitretin, cyclosporine‐A, and methotrexate. She was also treated with infliximab first and then adalimumab with optimal response of cutaneous and articular symptoms; however, during both biologics she developed ANA‐positivity with levels up to 1:1280 that were completely reversible after treatment suspension.Eight weeks after adalimumab discontinuation, the patient presented with a psoriasis area and severity index (PASI) score of 5, severe morning stiffness, visual analog scale (VAS) pain 6, important functional limitation with tender, swollen, and painful II, III, IV‐distal interphalangeal (DIP) and metacarpophalangeal (MCP) joints of both hands, and ultrasonographic active tenosynovitis of all the involved articulations. In addition, she developed new PsA symptoms at the right ankle and metatarsal sites of the right foot.The patient had http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Journal of Dermatology Wiley
Loading next page...
 
/lp/wiley/cutaneous-hyperpigmentation-induced-by-apremilast-uoo4fPfsvX
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
International Journal of Dermatology © 2018 International Society of Dermatology
ISSN
0011-9059
eISSN
1365-4632
D.O.I.
10.1111/ijd.13831
Publisher site
See Article on Publisher Site

Abstract

Case reportApremilast is an oral inhibitor of phosphodiesterase‐4 (PDE4) recently approved for the treatment of psoriasis and psoriatic arthritis (PsA).We report the case of a 70‐year‐old female patient affected with severe psoriasis and PsA for more than 30 years, who developed cutaneous skin hyperpigmentation while treated with oral apremilast 30 mg/bid (Fig. ).Patient before (a) and during apremilast treatment (b) exhibiting increase in size and darkening of the solar lentigines resembling intense UV exposureOver decades, she had been variously treated with PUVA, acitretin, cyclosporine‐A, and methotrexate. She was also treated with infliximab first and then adalimumab with optimal response of cutaneous and articular symptoms; however, during both biologics she developed ANA‐positivity with levels up to 1:1280 that were completely reversible after treatment suspension.Eight weeks after adalimumab discontinuation, the patient presented with a psoriasis area and severity index (PASI) score of 5, severe morning stiffness, visual analog scale (VAS) pain 6, important functional limitation with tender, swollen, and painful II, III, IV‐distal interphalangeal (DIP) and metacarpophalangeal (MCP) joints of both hands, and ultrasonographic active tenosynovitis of all the involved articulations. In addition, she developed new PsA symptoms at the right ankle and metatarsal sites of the right foot.The patient had

Journal

International Journal of DermatologyWiley

Published: Jan 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off